

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 May 2022 (05.05.2022)



(10) International Publication Number
WO 2022/094468 A1

(51) International Patent Classification:

G16B 15/00 (2019.01) *G16C 20/30* (2019.01)
G16B 15/30 (2019.01) *G16C 20/50* (2019.01)
G16B 40/20 (2019.01) *G16C 20/60* (2019.01)
G16C 20/00 (2019.01) *G16C 20/70* (2019.01)
G16C 20/10 (2019.01)

(21) International Application Number:

PCT/US2021/057731

(22) International Filing Date:

02 November 2021 (02.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/108,716 02 November 2020 (02.11.2020) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **ARORA, Jayant**; 82 Cedar Street, Edison, New Jersey 08820 (US). **TANG, Xiaolin**; 5 Eckerson Court, Old Tappan, New Jersey 07675 (US). **SHAMEEM, Mohammed**; 4 Surim Court, Nanuet, New York 10954 (US). **TAFAZZOL, Alireza**; 1868 Van Ness Avenue, Apartment 505, San Francisco, CA 94109 (US).

(74) Agent: **BROWN, Charley F.** et al.; BALLARD SPAHR LLP, 999 Peachtree Street, Suite 1600, Atlanta, Georgia 30309 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: METHODS AND SYSTEMS FOR BIOTHERAPEUTIC DEVELOPMENT




FIG. 2

(57) Abstract: Disclosed are methods comprising determining experimental data associated with one or more monoclonal antibodies (mAbs), determining computationally-derived data associated with the one or more mAbs, wherein the computationally-derived data comprises one or more computational parameters weighted based on accessible surfaces (ASAs) of one or more residues of the one or more mAbs, determining, based on the experimental data and the computationally-derived data, a plurality of candidate predictive models, determining an optimal predictive model from the plurality of candidate predictive models, and outputting the optimal predictive model.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*